MPD: All measures mapped to paradigm code 'ctrldoses'

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Crabbe1:3	Crabbe1	balance beam	ethanol	missteps crossing 12.7mm wide balance beam [n] bal12 15403 dose (g/kg) control 1.0 1.2 1.4	inbred	8	both	8-16wks	N=3	2003

Crabbe1:4	Crabbe1	balance beam	ethanol	missteps crossing 15.8mm wide balance beam [n] bal15 15404 dose (g/kg): control 1.0 1.2 1.4	inbred	8	both	8-16wks	N=3	2003

Crabbe1:5	Crabbe1	balance beam	ethanol	missteps crossing 19.0 mm wide balance beam [n] bal19 15405 dose (g/kg) control 1.0 1.2 1.4	inbred	8	both	8-16wks	N=3	2003

Crabbe1:6	Crabbe1	grid test	ethanol	grid habituation, distance traveled [cm] grid_dist 15406 dose (g/kg): control 1.5 2.0 2.5	inbred	8	both	8-16wks	N=12	2003

Crabbe1:7	Crabbe1	grid test	ethanol	grid habituation, missteps per cm [n/cm] grid_ataxia 15407 dose (g/kg): control 1.5 2.0 2.5	inbred	8	both	8-16wks	N=12	2003

Gould1:1	Gould1	forced swim test	lithium	duration of immobility [s] immob 37401 lithium dose [mg/kg]: 0(saline) 200 300 400	inbred	11	m	7-8wks	N=8	2011

Gould1:5	Gould1	drug and metabolite quantification	lithium	serum lithium concentration [mmol/L] blood_lithium 37405 lithium dose [mg/kg]: 200 300 400	inbred	11	m	7-8wks	N=8	2011

Gould1:8	Gould1	drug and metabolite quantification	lithium	brain lithium concentration [mmol/L] brain_lithium 37408 lithium dose [mg/kg]: 200 300 400	inbred	11	m	7-8wks	N=8	2011

Gould2:17	Gould2	fear conditioning test	nicotine	acute group, percent immobility in training chamber after first stimulus pairing [%] FC_immediate_acu 47131 dose (mg): control 0.045 0.09 0.18	inbred	8	m	8-12wks	N=11	2011

Gould2:21	Gould2	fear conditioning test	nicotine	acute group, percent immobility in training chamber, 24h after fear conditioning [%] FC_context_acu 47136 dose (mg): control 0.045 0.09 0.18	inbred	8	m	8-12wks	N=11	2011

Gould2:25	Gould2	fear conditioning test	nicotine	acute group, percent immobility in altered context chamber, pre-cue [%] FC_preCS_acu 47141 dose (mg): control 0.045 0.09 0.18	inbred	8	m	8-12wks	N=11	2011

Gould2:29	Gould2	fear conditioning test	nicotine	acute group, percent immobility in altered context chamber, cue [%] FC_CS_acu 47146 dose (mg) control 0.045 0.09 0.18	inbred	8	m	8-12wks	N=11	2011

Gould3:1	Gould3	behavior observation	nicotine	withdrawal study group, number of grooming episodes, 20 min test [n] grooming 47301 control nicotine dose (mg) 3 6.3 12	inbred	8	m	8-12wks	N=11	2011

Gould3:6	Gould3	behavior observation	nicotine	withdrawal study group, number of scratching episodes, 20 min test [n] scratching 47306 control nicotine dose (mg) 3 6.3 12	inbred	8	m	8-12wks	N=11	2011

Gould3:11	Gould3	behavior observation	nicotine	withdrawal study group, number of jumping episodes, 20 min test [n] jumping 47311 control nicotine dose (mg) 3 6.3 12	inbred	8	m	8-12wks	N=11	2011

Gould3:21	Gould3	elevated plus maze	nicotine	withdrawal study group, percentage of time in closed arms [%] EPM_pct_closed 47321 control nicotine dose (mg) 3 6.3 12	inbred	8	m	8-12wks	N=10	2011

Gould3:26	Gould3	elevated plus maze	nicotine	withdrawal study group, percentage of time in open arms [%] EPM_pct_open 47326 control nicotine dose (mg) 3 6.3 12	inbred	8	m	8-12wks	N=10	2011

Gould3:31	Gould3	elevated plus maze	nicotine	withdrawal study group, percentage of time in center [%] EPM_pct_center 47331 control nicotine dose (mg) 3 6.3 12	inbred	8	m	8-12wks	N=10	2011

Gould3:41	Gould3	fear conditioning test	nicotine	withdrawal study group, percent immobility in training chamber after first stimulus pairing [%] FC_immediate 47341 control nicotine dose (mg) 3 6.3 12	inbred	8	m	8-12wks	N=12	2011

Gould3:46	Gould3	fear conditioning test	nicotine	withdrawal study group, percent immobility in training chamber, 24h after fear conditioning [%] FC_context 47346 control nicotine dose (mg) 3 6.3 12	inbred	8	m	8-12wks	N=12	2011

Gould3:61	Gould3	fear conditioning test	nicotine	withdrawal study group, percent immobility in altered context chamber, pre-cue [%] FC_preCS 47361 control nicotine dose (mg) 3 6.3 12	inbred	8	m	8-12wks	N=12	2011

Gould3:66	Gould3	fear conditioning test	nicotine	withdrawal study group, percent immobility in altered context chamber, cue [%] FC_CS 47366 control nicotine dose (mg) 3 6.3 12	inbred	8	m	8-12wks	N=12	2011

Koide2:2	Koide2	nociception assay	(none)	capsaicin solution consumption, percentage of baseline [%] capsaicin 35802 concentration (µM): 0.5 1 4 7 10 15	wild-derived Mishima	14	both	8-12wks	N=10	2003

Maurer1:1	Maurer1	tail cuff	atenolol, isoproterenol	pulse rate [n/min] pulse 33201 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=11	2009

Maurer1:5	Maurer1	ECG	atenolol, isoproterenol	heart rate [n/min] HR 33205 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:9	Maurer1	tail cuff	atenolol, isoproterenol	systolic blood pressure [mmHg] BP 33209 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:13	Maurer1	ECG	atenolol, isoproterenol	amplitude of P-wave [mV] P_amp 33213 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:17	Maurer1	ECG	atenolol, isoproterenol	amplitude of Q-wave [mV] Q_amp 33217 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=9	2009

Maurer1:21	Maurer1	ECG	atenolol, isoproterenol	amplitude of R-wave [mV] R_amp 33221 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=9	2009

Maurer1:25	Maurer1	ECG	atenolol, isoproterenol	amplitude of S-wave [mV] S_amp 33225 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=9	2009

Maurer1:29	Maurer1	ECG	atenolol, isoproterenol	duration P-wave [ms] P_dur 33229 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:33	Maurer1	ECG	atenolol, isoproterenol	interval PR [ms] PR 33233 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:37	Maurer1	ECG	atenolol, isoproterenol	interval RR [ms] RR 33237 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:41	Maurer1	ECG	atenolol, isoproterenol	interval QRS [ms] QRS 33241 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:45	Maurer1	ECG	atenolol, isoproterenol	interval QT [ms] QT 33245 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:49	Maurer1	ECG	atenolol, isoproterenol	interval ST [ms] ST 33249 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:53	Maurer1	ECG	atenolol, isoproterenol	area of P-wave [ms*mV] Parea 33253 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=9	2009

Maurer1:57	Maurer1	ECG	atenolol, isoproterenol	area of QRS [ms*mV] QRSarea 33257 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=9	2009

Maurer1:61	Maurer1	ECG	atenolol, isoproterenol	area of QTc [ms*mV] QTc_area 33261 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:66	Maurer1	body weight	atenolol, isoproterenol	fold change in body weight over testing period [ratio] bwchg 33266 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:70	Maurer1	organ weights	atenolol, isoproterenol	heart weight [mg] heart_wt 33270 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=11	2009

Maurer1:74	Maurer1	organ weights	atenolol, isoproterenol	heart weight normalized to body weight [mg/g] heart_adjwt 33274 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=11	2009

Maurer1:78	Maurer1	organ weights	atenolol, isoproterenol	atria weight [mg] atria_wt 33278 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:82	Maurer1	organ weights	atenolol, isoproterenol	atria weight normalized to body weight [mg/g] atria_adjwt 33282 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

Maurer1:86	Maurer1	organ weights	atenolol, isoproterenol	ventricle (both) weight [mg] ventr_wt 33286 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=11	2009

Maurer1:90	Maurer1	organ weights	atenolol, isoproterenol	ventricle (both) weight normalized to body weight [mg/g] ventr_adjwt 33290 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=11	2009

Maurer1:94	Maurer1	organ weights	atenolol, isoproterenol	atria weight to ventricle weight ratio [ratio] atr_ventr 33294 control atenolol 10mg isoprot 1mg isoprot 10mg	inbred	23	m	7-13wks	N=10	2009

McMullan6:1	McMullan6	body weight	(none)	body weight at start of experiment [g] bw_start 61501 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan6:6	McMullan6	body weight	exercise	body weight at after 4 wks of treatment [g] bw_end 61506 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan6:11	McMullan6	body weight	exercise	body weight, response to 4 wks of treatment [%] bw_resp 61511 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan6:16	McMullan6	MRI	(none)	percentage of body mass that is fat at start of experiment [%] fat_start 61516 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan6:21	McMullan6	MRI	exercise	percentage of body mass that is fat after 4 wks of treatment [%] fat_end 61521 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan6:26	McMullan6	MRI	exercise	percentage of body mass that is fat, response after 4 wks of treatment [%] fat_resp 61526 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan6:31	McMullan6	MRI	(none)	percentage of body mass that is lean at start of experiment [%] lean_start 61531 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan6:36	McMullan6	MRI	exercise	percentage of body mass that is lean after 4 wks of treatment [%] lean_end 61536 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan6:41	McMullan6	MRI	exercise	percentage of body mass that is lean, response after 4 wks of treatment [%] lean_resp 61541 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:1	McMullan7	monitoring system	(none)	mean oxygen consumption at start of experiment, during day [mL/h] VO2_d_start 61601 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:4	McMullan7	monitoring system	exercise	mean oxygen consumption after 4 wks of treatment, during day [mL/h] VO2_d_end 61604 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:7	McMullan7	monitoring system	(none)	mean oxygen consumption at start of experiment, during night [mL/h] VO2_n_start 61607 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:11	McMullan7	monitoring system	exercise	mean oxygen consumption after 4 wks of treatment, during night [mL/h] VO2_n_end 61611 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:14	McMullan7	monitoring system	(none)	mean carbon dioxide production at start of experiment, during day [mL/h] VCO2_d_start 61614 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:17	McMullan7	monitoring system	exercise	mean carbon dioxide production after 4 wks of treatment, during day [mL/h] VCO2_d_end 61617 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:21	McMullan7	monitoring system	(none)	mean carbon dioxide production at start of experiment, during night [mL/h] VCO2_n_start 61621 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:24	McMullan7	monitoring system	exercise	mean carbon dioxide production after 4 wks of treatment, during night [mL/h] VCO2_n_end 61624 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:27	McMullan7	monitoring system	(none)	mean respiratory exchange rate at start of experiment, during day [ratio] RER_d_start 61627 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:31	McMullan7	monitoring system	exercise	mean respiratory exchange rate after 4 wks of treatment, during day [ratio] RER_d_end 61631 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:34	McMullan7	monitoring system	(none)	mean respiratory exchange rate at start of experiment, during night [ratio] RER_n_start 61634 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:37	McMullan7	monitoring system	exercise	mean respiratory exchange rate after 4 wks of treatment, during night [ratio] RER_n_end 61637 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:41	McMullan7	monitoring system	(none)	activity (beam breaks) at start of experiment, during day [n] act_d_start 61641 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:44	McMullan7	monitoring system	exercise	activity (beam breaks) after 4 wks of treatment, during day [n] act_d_end 61644 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:47	McMullan7	monitoring system	(none)	activity (beam breaks) at start of experiment, during night [n] act_n_start 61647 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:51	McMullan7	monitoring system	exercise	activity (beam breaks) after 4 wks of treatment, during night [n] act_n_end 61651 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:54	McMullan7	monitoring system	(none)	mean heat production at start of experiment, during day [kcal/h/kg] heat_d_start 61654 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:57	McMullan7	monitoring system	exercise	mean heat production after 4 wks of treatment, during day [kcal/h/kg] heat_d_end 61657 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:61	McMullan7	monitoring system	(none)	mean heat production at start of experiment, during night [kcal/h/kg] heat_n_start 61661 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:64	McMullan7	monitoring system	exercise	mean heat production after 4 wks of treatment, during night [kcal/h/kg] heat_n_end 61664 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:67	McMullan7	intake monitoring	(none)	total food intake at start of experiment, during day [g] food_d_start 61667 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:71	McMullan7	intake monitoring	exercise	total food intake after 4 wks of treatment, during day [g] food_d_end 61671 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:74	McMullan7	intake monitoring	(none)	total food intake at start of experiment, during night [g] food_n_start 61674 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:77	McMullan7	intake monitoring	exercise	total food intake after 4 wks of treatment, during night [g] food_n_end 61677 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:81	McMullan7	intake monitoring	(none)	total water intake at start of experiment, during day [mL] water_d_start 61681 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:84	McMullan7	intake monitoring	exercise	total water intake after 4 wks of treatment, during day [mL] water_d_end 61684 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:87	McMullan7	intake monitoring	(none)	total water intake at start of experiment, during night [mL] water_n_start 61687 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

McMullan7:91	McMullan7	intake monitoring	exercise	total water intake after 4 wks of treatment, during night [mL] water_n_end 61691 no exercise group moderate intensity group high intensity group	CC	4	both	8-10wks	N=8	2018

Threadgill1:1	Threadgill1	organ weights	acetaminophen	liver weight 24h after treatment [g] liverwt 19401 dose (mg/kg): control 100 200 300	inbred w/CC7	37	m	8-17wks	N=4	2005

Threadgill1:4	Threadgill1	histopathology	acetaminophen	necrosis [%] liver_necrosis 19404 dose (mg/kg): control 100 200 300	inbred w/CC7	37	m	8-17wks	N=2	2005

Threadgill1:10	Threadgill1	metabolic panel	acetaminophen	aspartate transaminase (serum AST) [IU/L] AST 19410 dose (mg/kg): control 100 200 300	inbred w/CC7	37	m	8-17wks	N=2	2005

Threadgill1:12	Threadgill1	metabolic panel	acetaminophen	blood urea nitrogen (serum BUN) [mg/dL] BUN 19412 dose (mg/kg) control 100 200 300	inbred w/CC7	37	m	8-17wks	N=2	2005

Wiltshire4:1	Wiltshire4	immune cell quantification	BEZ235	B cells, percent viability [%] Bcells_BEZ 52401 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:7	Wiltshire4	immune cell quantification	BEZ235	T cells, percent viability [%] Tcells_BEZ 52407 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:13	Wiltshire4	immune cell quantification	BEZ235	monocytes, percent viability [%] monocytes_BEZ 52413 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:21	Wiltshire4	immune cell quantification	doxorubicin	B cells, percent viability [%] Bcells_Dox 52421 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:27	Wiltshire4	immune cell quantification	doxorubicin	T cells, percent viability [%] Tcells_Dox 52427 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:33	Wiltshire4	immune cell quantification	doxorubicin	monocytes, percent viability [%] monocytes_Dox 52433 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:41	Wiltshire4	immune cell quantification	idarubicin	B cells, percent viability [%] Bcells_Ida 52441 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:47	Wiltshire4	immune cell quantification	idarubicin	T cells, percent viability [%] Tcells_Ida 52447 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:53	Wiltshire4	immune cell quantification	idarubicin	monocytes, percent viability [%] monocytes_Ida 52453 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:61	Wiltshire4	immune cell quantification	selumetinib	B cells, percent viability [%] Bcells_Sel 52461 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:67	Wiltshire4	immune cell quantification	selumetinib	T cells, percent viability [%] Tcells_Sel 52467 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:73	Wiltshire4	immune cell quantification	selumetinib	monocytes, percent viability [%] monocytes_Sel 52473 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Crabbe1

balance beam

ethanol

missteps crossing 12.7mm wide balance beam [n] bal12 15403 dose (g/kg) control 1.0 1.2 1.4

inbred

8

both

8-16wks

N=3

2003

Crabbe1

balance beam

ethanol

missteps crossing 15.8mm wide balance beam [n] bal15 15404 dose (g/kg): control 1.0 1.2 1.4

inbred

8

both

8-16wks

N=3

2003

Crabbe1

balance beam

ethanol

missteps crossing 19.0 mm wide balance beam [n] bal19 15405 dose (g/kg) control 1.0 1.2 1.4

inbred

8

both

8-16wks

N=3

2003

Crabbe1

grid test

ethanol

grid habituation, distance traveled [cm] grid_dist 15406 dose (g/kg): control 1.5 2.0 2.5

inbred

8

both

8-16wks

N=12

2003

Crabbe1

grid test

ethanol

grid habituation, missteps per cm [n/cm] grid_ataxia 15407 dose (g/kg): control 1.5 2.0 2.5

inbred

8

both

8-16wks

N=12

2003

Gould1

forced swim test

lithium

duration of immobility [s] immob 37401 lithium dose [mg/kg]: 0(saline) 200 300 400

inbred

11

m

7-8wks

N=8

2011

Gould1

drug and metabolite quantification

lithium

serum lithium concentration [mmol/L] blood_lithium 37405 lithium dose [mg/kg]: 200 300 400

inbred

11

m

7-8wks

N=8

2011

Gould1

drug and metabolite quantification

lithium

brain lithium concentration [mmol/L] brain_lithium 37408 lithium dose [mg/kg]: 200 300 400

inbred

11

m

7-8wks

N=8

2011

Gould2

fear conditioning test

nicotine

acute group, percent immobility in training chamber after first stimulus pairing [%] FC_immediate_acu 47131 dose (mg): control 0.045 0.09 0.18

inbred

8

m

8-12wks

N=11

2011

Gould2

fear conditioning test

nicotine

acute group, percent immobility in training chamber, 24h after fear conditioning [%] FC_context_acu 47136 dose (mg): control 0.045 0.09 0.18

inbred

8

m

8-12wks

N=11

2011

Gould2

fear conditioning test

nicotine

acute group, percent immobility in altered context chamber, pre-cue [%] FC_preCS_acu 47141 dose (mg): control 0.045 0.09 0.18

inbred

8

m

8-12wks

N=11

2011

Gould2

fear conditioning test

nicotine

acute group, percent immobility in altered context chamber, cue [%] FC_CS_acu 47146 dose (mg) control 0.045 0.09 0.18

inbred

8

m

8-12wks

N=11

2011

Gould3

behavior observation

nicotine

withdrawal study group, number of grooming episodes, 20 min test [n] grooming 47301 control nicotine dose (mg) 3 6.3 12

inbred

8

m

8-12wks

N=11

2011

Gould3

behavior observation

nicotine

withdrawal study group, number of scratching episodes, 20 min test [n] scratching 47306 control nicotine dose (mg) 3 6.3 12

inbred

8

m

8-12wks

N=11

2011

Gould3

behavior observation

nicotine

withdrawal study group, number of jumping episodes, 20 min test [n] jumping 47311 control nicotine dose (mg) 3 6.3 12

inbred

8

m

8-12wks

N=11

2011

Gould3

elevated plus maze

nicotine

withdrawal study group, percentage of time in closed arms [%] EPM_pct_closed 47321 control nicotine dose (mg) 3 6.3 12

inbred

8

m

8-12wks

N=10

2011

Gould3

elevated plus maze

nicotine

withdrawal study group, percentage of time in open arms [%] EPM_pct_open 47326 control nicotine dose (mg) 3 6.3 12

inbred

8

m

8-12wks

N=10

2011

Gould3

elevated plus maze

nicotine

withdrawal study group, percentage of time in center [%] EPM_pct_center 47331 control nicotine dose (mg) 3 6.3 12

inbred

8

m

8-12wks

N=10

2011

Gould3

fear conditioning test

nicotine

withdrawal study group, percent immobility in training chamber after first stimulus pairing [%] FC_immediate 47341 control nicotine dose (mg) 3 6.3 12

inbred

8

m

8-12wks

N=12

2011

Gould3

fear conditioning test

nicotine

withdrawal study group, percent immobility in training chamber, 24h after fear conditioning [%] FC_context 47346 control nicotine dose (mg) 3 6.3 12

inbred

8

m

8-12wks

N=12

2011

Gould3

fear conditioning test

nicotine

withdrawal study group, percent immobility in altered context chamber, pre-cue [%] FC_preCS 47361 control nicotine dose (mg) 3 6.3 12

inbred

8

m

8-12wks

N=12

2011

Gould3

fear conditioning test

nicotine

withdrawal study group, percent immobility in altered context chamber, cue [%] FC_CS 47366 control nicotine dose (mg) 3 6.3 12

inbred

8

m

8-12wks

N=12

2011

Koide2

nociception assay

(none)

capsaicin solution consumption, percentage of baseline [%] capsaicin 35802 concentration (µM): 0.5 1 4 7 10 15

wild-derived Mishima

14

both

8-12wks

N=10

2003

Maurer1

tail cuff

atenolol, isoproterenol

pulse rate [n/min] pulse 33201 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=11

2009

Maurer1

ECG

atenolol, isoproterenol

heart rate [n/min] HR 33205 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

Maurer1

tail cuff

atenolol, isoproterenol

systolic blood pressure [mmHg] BP 33209 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

Maurer1

ECG

atenolol, isoproterenol

amplitude of P-wave [mV] P_amp 33213 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

Maurer1

ECG

atenolol, isoproterenol

amplitude of Q-wave [mV] Q_amp 33217 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=9

2009

Maurer1

ECG

atenolol, isoproterenol

amplitude of R-wave [mV] R_amp 33221 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=9

2009

Maurer1

ECG

atenolol, isoproterenol

amplitude of S-wave [mV] S_amp 33225 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=9

2009

Maurer1

ECG

atenolol, isoproterenol

duration P-wave [ms] P_dur 33229 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

Maurer1

ECG

atenolol, isoproterenol

interval PR [ms] PR 33233 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

Maurer1

ECG

atenolol, isoproterenol

interval RR [ms] RR 33237 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

Maurer1

ECG

atenolol, isoproterenol

interval QRS [ms] QRS 33241 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

Maurer1

ECG

atenolol, isoproterenol

interval QT [ms] QT 33245 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

Maurer1

ECG

atenolol, isoproterenol

interval ST [ms] ST 33249 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

Maurer1

ECG

atenolol, isoproterenol

area of P-wave [ms*mV] Parea 33253 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=9

2009

Maurer1

ECG

atenolol, isoproterenol

area of QRS [ms*mV] QRSarea 33257 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=9

2009

Maurer1

ECG

atenolol, isoproterenol

area of QTc [ms*mV] QTc_area 33261 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

Maurer1

body weight

atenolol, isoproterenol

fold change in body weight over testing period [ratio] bwchg 33266 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

Maurer1

organ weights

atenolol, isoproterenol

heart weight [mg] heart_wt 33270 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=11

2009

Maurer1

organ weights

atenolol, isoproterenol

heart weight normalized to body weight [mg/g] heart_adjwt 33274 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=11

2009

Maurer1

organ weights

atenolol, isoproterenol

atria weight [mg] atria_wt 33278 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

Maurer1

organ weights

atenolol, isoproterenol

atria weight normalized to body weight [mg/g] atria_adjwt 33282 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

Maurer1

organ weights

atenolol, isoproterenol

ventricle (both) weight [mg] ventr_wt 33286 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=11

2009

Maurer1

organ weights

atenolol, isoproterenol

ventricle (both) weight normalized to body weight [mg/g] ventr_adjwt 33290 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=11

2009

Maurer1

organ weights

atenolol, isoproterenol

atria weight to ventricle weight ratio [ratio] atr_ventr 33294 control atenolol 10mg isoprot 1mg isoprot 10mg

inbred

23

m

7-13wks

N=10

2009

McMullan6

body weight

(none)

body weight at start of experiment [g] bw_start 61501 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan6

body weight

exercise

body weight at after 4 wks of treatment [g] bw_end 61506 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan6

body weight

exercise

body weight, response to 4 wks of treatment [%] bw_resp 61511 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan6

MRI

(none)

percentage of body mass that is fat at start of experiment [%] fat_start 61516 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan6

MRI

exercise

percentage of body mass that is fat after 4 wks of treatment [%] fat_end 61521 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan6

MRI

exercise

percentage of body mass that is fat, response after 4 wks of treatment [%] fat_resp 61526 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan6

MRI

(none)

percentage of body mass that is lean at start of experiment [%] lean_start 61531 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan6

MRI

exercise

percentage of body mass that is lean after 4 wks of treatment [%] lean_end 61536 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan6

MRI

exercise

percentage of body mass that is lean, response after 4 wks of treatment [%] lean_resp 61541 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

(none)

mean oxygen consumption at start of experiment, during day [mL/h] VO2_d_start 61601 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

exercise

mean oxygen consumption after 4 wks of treatment, during day [mL/h] VO2_d_end 61604 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

(none)

mean oxygen consumption at start of experiment, during night [mL/h] VO2_n_start 61607 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

exercise

mean oxygen consumption after 4 wks of treatment, during night [mL/h] VO2_n_end 61611 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

(none)

mean carbon dioxide production at start of experiment, during day [mL/h] VCO2_d_start 61614 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

exercise

mean carbon dioxide production after 4 wks of treatment, during day [mL/h] VCO2_d_end 61617 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

(none)

mean carbon dioxide production at start of experiment, during night [mL/h] VCO2_n_start 61621 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

exercise

mean carbon dioxide production after 4 wks of treatment, during night [mL/h] VCO2_n_end 61624 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

(none)

mean respiratory exchange rate at start of experiment, during day [ratio] RER_d_start 61627 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

exercise

mean respiratory exchange rate after 4 wks of treatment, during day [ratio] RER_d_end 61631 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

(none)

mean respiratory exchange rate at start of experiment, during night [ratio] RER_n_start 61634 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

exercise

mean respiratory exchange rate after 4 wks of treatment, during night [ratio] RER_n_end 61637 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

(none)

activity (beam breaks) at start of experiment, during day [n] act_d_start 61641 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

exercise

activity (beam breaks) after 4 wks of treatment, during day [n] act_d_end 61644 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

(none)

activity (beam breaks) at start of experiment, during night [n] act_n_start 61647 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

exercise

activity (beam breaks) after 4 wks of treatment, during night [n] act_n_end 61651 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

(none)

mean heat production at start of experiment, during day [kcal/h/kg] heat_d_start 61654 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

exercise

mean heat production after 4 wks of treatment, during day [kcal/h/kg] heat_d_end 61657 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

(none)

mean heat production at start of experiment, during night [kcal/h/kg] heat_n_start 61661 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

monitoring system

exercise

mean heat production after 4 wks of treatment, during night [kcal/h/kg] heat_n_end 61664 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

intake monitoring

(none)

total food intake at start of experiment, during day [g] food_d_start 61667 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

intake monitoring

exercise

total food intake after 4 wks of treatment, during day [g] food_d_end 61671 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

intake monitoring

(none)

total food intake at start of experiment, during night [g] food_n_start 61674 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

intake monitoring

exercise

total food intake after 4 wks of treatment, during night [g] food_n_end 61677 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

intake monitoring

(none)

total water intake at start of experiment, during day [mL] water_d_start 61681 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

intake monitoring

exercise

total water intake after 4 wks of treatment, during day [mL] water_d_end 61684 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

intake monitoring

(none)

total water intake at start of experiment, during night [mL] water_n_start 61687 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

McMullan7

intake monitoring

exercise

total water intake after 4 wks of treatment, during night [mL] water_n_end 61691 no exercise group moderate intensity group high intensity group

CC

4

both

8-10wks

N=8

2018

Threadgill1

organ weights

acetaminophen

liver weight 24h after treatment [g] liverwt 19401 dose (mg/kg): control 100 200 300

inbred w/CC7

37

m

8-17wks

N=4

2005

Threadgill1

histopathology

acetaminophen

necrosis [%] liver_necrosis 19404 dose (mg/kg): control 100 200 300

inbred w/CC7

37

m

8-17wks

N=2

2005

Threadgill1

metabolic panel

acetaminophen

aspartate transaminase (serum AST) [IU/L] AST 19410 dose (mg/kg): control 100 200 300

inbred w/CC7

37

m

8-17wks

N=2

2005

Threadgill1

metabolic panel

acetaminophen

blood urea nitrogen (serum BUN) [mg/dL] BUN 19412 dose (mg/kg) control 100 200 300

inbred w/CC7

37

m

8-17wks

N=2

2005

Wiltshire4

immune cell quantification

BEZ235

B cells, percent viability [%] Bcells_BEZ 52401 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

34

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

BEZ235

T cells, percent viability [%] Tcells_BEZ 52407 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

34

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

BEZ235

monocytes, percent viability [%] monocytes_BEZ 52413 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

34

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

doxorubicin

B cells, percent viability [%] Bcells_Dox 52421 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

35

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

doxorubicin

T cells, percent viability [%] Tcells_Dox 52427 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

35

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

doxorubicin

monocytes, percent viability [%] monocytes_Dox 52433 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

35

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

idarubicin

B cells, percent viability [%] Bcells_Ida 52441 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

35

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

idarubicin

T cells, percent viability [%] Tcells_Ida 52447 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

35

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

idarubicin

monocytes, percent viability [%] monocytes_Ida 52453 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

35

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

selumetinib

B cells, percent viability [%] Bcells_Sel 52461 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

34

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

selumetinib

T cells, percent viability [%] Tcells_Sel 52467 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

34

m

10wks

N=4

2015

Wiltshire4

immune cell quantification

selumetinib

monocytes, percent viability [%] monocytes_Sel 52473 dose [µM]: control 0.046 0.137 1.235 11.1 100

inbred w/CC7

34

m

10wks

N=4

2015

Study designs: all MPD measure sets of study design type ctrldoses

Filter Table Results